BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Amount of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-24.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationDeductionsQualifiedProductionActivities · last filed 2020-02-24
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, deduction, qualified production activity, amount for fiscal 2019 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, deduction, qualified production activity, amount for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, deduction, qualified production activity, amount for fiscal 2017 was $78.00M, a 36.07% decline from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, deduction, qualified production activity, amount for fiscal 2016 was $122.00M, a 617.65% increase from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Amount 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-24 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-24 |
| 2017-12-31 | $78.00M 10-K · filed 2020-02-24 |
| 2016-12-31 | $122.00M 10-K · filed 2019-02-25 |
| 2015-12-31 | $17.00M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |